Vasoactive role for angiotensin II type 2 receptors in human radial artery

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 1, 2014, Pages 79-85

  Zulli, Anthony ^a,b   Hare, D L ^b,c   Buxton, B F ^c   Widdop, R E ^d  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

AT1 receptors; AT2 receptors; Human blood vessels; Immunohistochemistry; Intimal thickening

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CANDESARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIAL ARTERY; VASOCONSTRICTION; DRUG EFFECT; IN VITRO STUDY; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASODILATATION; BLOOD PRESSURE; DOSE RESPONSE;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; PYRIDINES; RADIAL ARTERY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; VASOCONSTRICTION; VASODILATION;

EID: 84900564222     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700110     Document Type: Article

References (24)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52(3):415-72.
2. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83(12):1182-91. (Pubitemid 29006033)
3. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003; 140(5):809-24. (Pubitemid 37464062)
4. Zulli A, Burrell LM, Widdop RE, Black MJ, Buxton BF, Hare DL. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 2006; 54:147-50. (Pubitemid 43201635)
5. Johansson ME, Fagerberg B, Bergstrom G. Angiotensin type 2 receptor is expressed in human atherosclerotic lesions. J Renin Angiotensin Aldosterone Syst 2008; 9(1):17-21. (Pubitemid 351546629)
6. .Barker TA, Massett MP, Korshunov VA, Mohan AM, Kennedy AJ, Berk BC. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Hypertension 2006; 48(5):942-49. (Pubitemid 44611009)
7. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120(3):292-316.
8. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004; 109:2296-301. (Pubitemid 38656868)
9. van de Wal RM, van der Harst P, Wagenaar LJ, et al. Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. J Cardiovasc Pharmacol 2007; 50:372-79. (Pubitemid 350303814)
10. Zhuo JL, Froomes P, Casley D, Liu JJ, Murone C, Chai SY, Buxton B, Mendelsohn FA. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96:174-82. (Pubitemid 27298419)
11. Ruengsakulrach P, Sinclair R, Komeda M, Raman J, Gordon I, Buxton B. Comparative histopathology of radial artery versus internal thoracic artery and risk factors for development of intimal hyperplasia and atherosclerosis. Circulation 1999; 100(S):II139-144.
12. He GW, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol 1988; 12:12-22.
13. Zulli A, Buxton BF, Black MJ, Hare DL. Embryonic stem cells markers are present within rabbit atherosclerotic plaques. Histol Histopathol 2008; 23:741-46. (Pubitemid 351552359)
14. Zulli A, Lau E, Wijaya BP, et al. High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. Hypertension 2009; 53(6): 1017-22.
15. You D, Loufrani L, Baron C, Levy BI, Widdop RE, Henrion D. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 2005; 111(8):1006-11. (Pubitemid 40354518)
16. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007; 49(2):341-46. (Pubitemid 46143011)
17. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40(4):516-20.
18. Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010; 127(10):2279-91.
19. Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008; 8(2):312-18.
20. Zulli A, Buxton BF, Black MJ, Ming Z, Cameron A, Hare DL. The immunoquantification of caveolin-1 and eNOS in human and rabbit diseased blood vessels. J Histochem Cytochem 2006; 54(2):151-59. (Pubitemid 43201636)
21. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121-31. (Pubitemid 24180877)
22. Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006; 26:2688-95.
23. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114(8):838-54.
24. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005; 18(S):134-41.